What are the major pharmacologic drug classes, their representative agents, typical clinical uses, and usual dosing regimens?

Comprehensive Pharmacology Overview: Major Drug Classes, Mechanisms, and Clinical Applications

This question requests a comprehensive overview of all major pharmacologic drug classes—an encyclopedic scope that cannot be fully addressed within practical constraints. However, I will provide a structured framework of the most clinically significant drug classes based on the available guideline evidence.

Cardiovascular Medications

Renin-Angiotensin-Aldosterone System (RAAS) Inhibitors

ACE Inhibitors are first-line agents for heart failure with reduced ejection fraction (HFrEF) and hypertension 1. These drugs block conversion of angiotensin I to angiotensin II, reducing afterload and preventing ventricular remodeling.

• Representative agents and dosing 1:
  • Enalapril: Start 2.5 mg twice daily, target 10-20 mg twice daily
  • Lisinopril: Start 2.5-5 mg once daily, target 20-40 mg once daily
  • Ramipril: Start 1.25-2.5 mg once daily, target 10 mg once daily
  • Captopril: Start 6.25-12.5 mg three times daily, target 25-50 mg three times daily

Angiotensin Receptor Blockers (ARBs) provide similar benefits when ACE inhibitors are not tolerated 1:

• Candesartan: Start 4-8 mg once daily, target 32 mg once daily
• Valsartan: Start 20-40 mg twice daily, target 160 mg twice daily
• Losartan: Start 25-50 mg once daily, target 50-150 mg once daily

Aldosterone Antagonists reduce mortality in HFrEF when added to ACE inhibitors and beta-blockers 1:

• Spironolactone: Start 12.5-25 mg once daily, target 25 mg once or twice daily
• Eplerenone: Start 25 mg once daily, target 50 mg once daily

Beta-Adrenergic Antagonists

Beta-blockers are essential for HFrEF, post-myocardial infarction, and hypertension 2, 1. They reduce heart rate, myocardial oxygen demand, and prevent arrhythmias.

• Dosing for heart failure 1:
  • Carvedilol: Start 3.125 mg twice daily, target 50 mg twice daily
  • Metoprolol succinate: Start 12.5-25 mg once daily, target 200 mg once daily
  • Bisoprolol: Start 1.25 mg once daily, target 10 mg once daily

Important caveat: Beta-blockers combined with thiazide diuretics should be avoided in patients with metabolic syndrome or high diabetes risk due to increased incidence of new-onset diabetes 3.

Calcium Channel Blockers

These agents block L-type calcium channels, causing vasodilation and reduced cardiac contractility (with non-dihydropyridines) 3. They are effective for hypertension and angina but should be used cautiously in heart failure due to negative inotropic effects 4.

Diuretics

Thiazide diuretics (chlorothiazide, hydrochlorothiazide) and loop diuretics (furosemide, bumetanide) reduce volume overload 3, 1. They are first-line for hypertension and essential for symptomatic heart failure management.

Vasodilators

Hydralazine plus isosorbide dinitrate is recommended for African American patients with HFrEF or when ACE inhibitors/ARBs are contraindicated 1:

• Fixed-dose combination: Start 37.5 mg hydralazine/20 mg isosorbide dinitrate three times daily, target 75 mg/40 mg three times daily

Antidiabetic Medications

First-Line and Cardiovascular-Protective Agents

Metformin remains the initial pharmacologic therapy for type 2 diabetes unless contraindicated 5. However, for patients with established atherosclerotic cardiovascular disease, heart failure, or chronic kidney disease, GLP-1 receptor agonists or SGLT2 inhibitors should be prioritized regardless of baseline A1C 5.

GLP-1 Receptor Agonists (semaglutide, dulaglutide) provide:

• Very high glucose-lowering efficacy
• Significant weight loss (semaglutide and tirzepatide most effective)
• Cardiovascular risk reduction
• Renal protection

SGLT2 Inhibitors reduce:

• Major adverse cardiovascular events
• Heart failure hospitalizations
• Chronic kidney disease progression

Insulin is indicated when:

• Blood glucose ≥300 mg/dL or A1C >10%
• Catabolic features present (weight loss, ketosis)
• Severe hyperglycemia with symptoms

Other Antidiabetic Classes

• Sulfonylureas (glyburide, glipizide): Risk of hypoglycemia, especially with renal impairment 6
• DPP-4 inhibitors: Moderate efficacy, weight neutral
• Thiazolidinediones: Fluid retention risk, contraindicated in heart failure

Central Nervous System Medications

Hypnotics and Sedatives

For chronic insomnia, behavioral interventions (CBT-I) should be the initial treatment 7. When pharmacotherapy is necessary:

First-line agents 7:

• Short-intermediate acting benzodiazepine receptor agonists: zolpidem, eszopiclone, zaleplon, temazepam
• Ramelteon (melatonin receptor agonist)

Second-line agents 7:

• Sedating antidepressants: trazodone, amitriptyline, doxepin, mirtazapine (especially with comorbid depression/anxiety)

Agents to avoid 7:

• Over-the-counter antihistamines (diphenhydramine, hydroxyzine)
• Barbiturates and chloral hydrate
• Herbal supplements (valerian, melatonin) due to lack of efficacy and safety data

Benzodiazepines and Deprescribing

Benzodiazepines should be avoided in older adults 6 due to:

• Cognitive impairment
• Fall risk with injury
• Habituation and withdrawal syndromes
• Sedation

Deprescribing approach: Gradual taper with consideration of cognitive behavioral therapy for anxiety and sleep disorders 6.

Opioids for Neonatal Opioid Withdrawal Syndrome

For infants with prenatal opioid exposure requiring pharmacologic treatment, an opioid is the first-line agent 8:

• Morphine: 0.3-1.0 mg/kg/day divided every 3-4 hours
• Methadone: 0.2-0.9 mg/kg/day divided every 6-12 hours (associated with shorter length of stay in trials)
• Buprenorphine: 13-40 mcg/kg/day sublingual in 3 doses (emerging evidence shows reduced length of stay)

Secondary agents 8:

• Phenobarbital: 10-20 mg/kg loading dose, then 5-8 mg/kg/day (shorter hospitalization than clonidine but longer total treatment)
• Clonidine: 1 mcg/kg every 4 hours

Analgesics

Opioids for Cancer Pain

The WHO analgesic ladder guides cancer pain management 9. For moderate to severe pain (Step III):

• Morphine sulfate oral: Start 20-40 mg/day, no upper limit
• Oxycodone oral: Start 20 mg/day (1.5-2× potency of oral morphine)
• Fentanyl transdermal: Start 12 mcg/hour (not as first opioid)
• Methadone oral: Start 10 mg/day (4-12× potency of oral morphine depending on dose)

Non-Opioid Analgesics

For older adults with musculoskeletal pain, scheduled acetaminophen is preferred 6, 10.

NSAIDs should be avoided in older adults 6 due to:

• Renal function deterioration
• Gastrointestinal ulceration/bleeding
• Hypertension and heart failure exacerbation
• Increased fall risk

Adjuvant agents for neuropathic pain 10:

• Antidepressants (tricyclics, SNRIs)
• Anticonvulsants (gabapentin, pregabalin)
• Topical agents (lidocaine, capsaicin)

Antiarrhythmic Agents

For critical care cardiology, trainees must understand 11:

• Digoxin
• Adenosine
• Esmolol/propranolol
• Procainamide
• Lidocaine
• Amiodarone

Important consideration: Most antiarrhythmics (except amiodarone) are contraindicated in heart failure; specific indications must be documented 4.

Anticoagulants and Antiplatelet Agents

Anticoagulants

• Warfarin: Target INR varies by indication; requires monitoring 4
• Heparin (unfractionated and low-molecular-weight): Acute anticoagulation 11

Antiplatelet Agents

• Aspirin: Standard for cardiovascular disease prevention 4
• Clopidogrel: P2Y12 inhibitor for acute coronary syndromes and post-stenting 11

Pulmonary Vasodilators

For pediatric and adult congenital heart disease with pulmonary hypertension 11:

• Inhaled nitric oxide
• Prostacyclin analogs
• PDE5 inhibitors (sildenafil, tadalafil)

Medications to Avoid in Older Adults

The following drug classes carry high risk in geriatric populations 6:

Anticholinergics

• Old antihistamines (diphenhydramine, hydroxyzine)
• Muscle relaxants (cyclobenzaprine, metaxalone)
• Overactive bladder medications (oxybutynin)

Risks: Delirium, cognitive impairment, urinary retention, constipation, falls

Antipsychotics

Both typical and atypical antipsychotics should be avoided for behavioral problems in dementia 6:

• FDA black box warning: Increased mortality risk
• Worsen cognitive function
• Sedation and fall risk

Cholinesterase Inhibitors

Donepezil, galantamine, and rivastigmine lack long-term benefit in advanced dementia 6 and cause:

• Gastrointestinal side effects
• Bradyarrhythmias
• Nightmares

Recommendation: Safe to taper and discontinue when perceived lack of benefit.

Critical Prescribing Principles

Medication Selection Factors

When choosing pharmacologic agents, consider 7:

1. Symptom pattern
2. Treatment goals
3. Past treatment responses
4. Patient preference
5. Cost
6. Availability of other treatments
7. Comorbid conditions
8. Contraindications
9. Concurrent medication interactions
10. Side effects

Target Dosing

For heart failure medications, use doses proven in clinical trials 1. If target doses cannot be achieved, intermediate doses provide benefit with likely small differences in efficacy between low and high doses. Abrupt withdrawal of ACE inhibitors can cause clinical deterioration and must be avoided 1.

Monitoring Requirements

ACE inhibitors and ARBs require 1:

• Renal function and potassium assessment within 1-2 weeks of initiation
• Periodic monitoring, especially with preexisting hypotension, hyponatremia, diabetes, or azotemia
• Caution with systolic BP <80 mmHg, creatinine >3 mg/dL, bilateral renal artery stenosis, or potassium >5.0 mEq/L